| Details description |
|---|
|
Manufactured by: Everest Pharmaceuticals Olanib 150 mg (Olaparib) is an oral anticancer medication classified as a Poly (ADP-ribose) polymerase (PARP) inhibitor. It is specifically designed to target and inhibit the PARP enzyme, which plays a critical role in repairing damaged DNA in cells. By inhibiting PARP, Olanib causes accumulation of DNA damage in cancer cells, leading to their death, particularly in tumors that already have compromised DNA repair mechanisms. Indications:Olanib 150 mg is primarily used for the treatment of:
It is often prescribed for patients with tumors that harbor BRCA1 or BRCA2 gene mutations, as these cancers rely heavily on PARP for DNA repair. Olanib exploits this vulnerability, resulting in selective killing of cancer cells while sparing normal cells. Mechanism of Action:Cancer cells with defective BRCA genes have impaired ability to repair double-strand DNA breaks via homologous recombination. They depend more on the PARP pathway to fix single-strand breaks. By blocking PARP activity, Olanib induces synthetic lethality, selectively killing BRCA-mutated cancer cells. Dosage and Administration:Olanib 150 mg tablets are typically taken orally twice daily or as prescribed by an oncologist. Treatment duration and dosage may vary based on cancer type, patient response, and tolerance. Side Effects:Common side effects may include nausea, fatigue, anemia, vomiting, diarrhea, and decreased appetite. Regular monitoring by healthcare providers is essential to manage side effects and adjust treatment. Category:
Olanib 150 mg belongs to the targeted cancer therapy category, specifically PARP inhibitors, and is part of precision oncology aimed at personalized treatment based on genetic tumor profiling. 🧪 Pharmaceutical Category:
💊 Therapeutic Class:
📋 Indication-Based Category:
🩺 Used In Treatment Of:
|
